THE ASCO GI symposium offers new, innovative findings in GI cancer treatment, research, and care.
The 2022 ASCO GI is happening in San Francisco from 1/20 - 1/22 this year. I’ll be attending the conference.
During the symposium, companies will be presenting clinical trial updates, which can be great catalyst for biopharma plays.
Here are some tickers to watch out for:
-
CRDF - Cardiff Oncology Inc.
Drug - Onvansertib, FOLFIRI and AVASTIN (bevacizumab)
Intended for - KRAS-Mutated Colorectal Cancer
Catalyst - Phase 1b/2 data displayed 42% of patients achieved an initial partial response (PR) as of the data cutoff date, 37% have achieved a confirmed PR. Treatment is shown to be well-tolerated with only 10% of reported treatment-emergent adverse events. - September 8 2021. Phase 1b/2 data to be presented at ASCO-GI with an abstract to be released January 18 and a presentation on January 22, 2022. -
ALKS - Alkermes plc (ALKS)
Drug - Nemvaleukin (ALKS 4230) - ARTISTRY-1
Intended for - Solid tumors
Catalyst - Phase 1/2 data presented at ASCO June 4, 2021. 2/6 patients in melanoma monotherapy cohort showed partial responses. Phase 1/2 additional clinical data to be presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, January 20-22, 2022. -
EXEL - Exelixis, Inc.
Drug - Cabozantinib with Atezolizumab - (COSMIC-021)
Intended for - Colorectal cancer (CRC)
Catalyst - Phase 1b data to be presented at ASCO January 20-22, 2022.
Drug - Cabozantinib with Durvalumab +/- Tremelimumab - (CAMILLA)
Intended for - Solid Tumors
Catalyst - Phase 1/2 results to be presented at ASCO January 20-22, 2022. -
PBLA - Panbela Therapeutics, Inc.
Drug - SBP101
Intended for - Pancreatic Cancer
Catalyst - Phase 1b data presented at ASCO June 4-8, 2021. In cohort 2 (N=7) the objective response rate (ORR) was 71%, and the disease control rate (DCR) was 100%. Phase 1b efficacy data to be presented at ASCO January 20-22, 2022. Randomized trial to be initiated by end of 2021. -
AZN - AstraZeneca PLC
Drug - IMFINZI (Durvalumab) + tremelimumab - (HIMALAYA)
Intended for - Hepatocellular carcinoma (HCC)
Catalyst - Phase 3 trial met primary endpoint of overall survival with a single priming dose every four weeks vs. sorafenib, noted October 15, 2021. Additional Phase 3 data to be presented on January 21, 2022 at ASCO GI 2022.
Drug - IMFINZI (Durvalumab) - (TOPAZ-1)
Intended for - Biliary-tract cancer
Catalyst - Phase 3 interim analysis reported trial met primary endpoint of improvement in OS versus standard of care. The trial also met key secondary endpoints, noted October 25, 2021. Phase 3 new data to be presented on January 21, 2022 at ASCO GI 2022. -
TYME - Tyme Technologies, Inc.
Drug - SM-88 and Gemcitabine (PanCAN_Precision Promise)
Intended for - Pancreatic Cancer
Catalyst - Phase 2/3 final study data to be presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 20 – 22, 2022. -
IBRX - ImmunityBio, Inc.
Drug - t-haNK and Anktiva (N-803) - (QUILT-88)
Intended for - Pancreatic cancer
Catalyst - Phase 2 data to be presented at ASCO Gastrointestinal Cancers Symposium, January 20-22 2022. -
AVEO - AVEO Pharmaceuticals, Inc.
Drug - FOTIVDA (Tivozanib) and IMFINZI (Durvalumab) - (DEDUCTIVE)
Intended for - Hepatocellular carcinoma (HCC)
Catalyst - Phase 1b/2 trial has moved to Phase 2 part of trial - May 29, 2020. Phase 1b data presented at ASCO GI January 15, 2021. 29% partial response (PR) rate. Data from first line cohort to be presented at ASCO GI in January 2022.
Out of these, what I’m particularly interested in is AZN, IBRX and TYME.
I’ll share any updates and/or whispers as the conference goes.
Cheers.